Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ESLA vs VIVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ESLA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–0 Matrix Metrics)

ESLA Overall Winner 6-Pillar Tally: ESLA 3 – 2 VIVS (1 Tie) Matrix Metrics: ESLA 6 – 0 VIVS

As of Nov 19, 2026, Estrella Immunopharma, Inc. (ESLA) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ESLA carries a Unified Composite Score of 46.0/100 (HOLD) at $0.34 (N/M Forward P/E, 0.0% operating margin), whereas VIVS carries 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin).

  • Technical & Structure Timing Caution: ESLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.5); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ESLA vs VIVS
ESLA NASDAQ Head-to-Head Winner
Estrella Immunopharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.34
+2.25% 1D
Market Cap $14.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.56β · 339% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 50.0 Fund 51.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.0%), weak momentum, RSI 41
RSI-14: 41.5 · SMA20: $0.58 · SMA50: $0.52
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.83β · 480% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 5.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.1 · SMA20: $0.15 · SMA50: $0.18

6-Pillar Scorecard Institutional Category Breakdown (ESLA 3 – 2 VIVS)

Columns: Metric · ESLA · VIVS
1. Valuation Multiples VIVS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 9.6x
2. Growth & Scale ESLA
Revenue Growth (YoY) +0.0% -51.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $112,000
Market Cap $14.6M $2.4M
3. Profitability & Quality ESLA
Gross Margin N/A N/A
Operating Margin 0.0% -10117.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -268.5% -343.1%
4. Balance Sheet & Cash Flow VIVS
Cash Generation (TTM) -$9.4M -$11M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage -268.5% ROE $1.4M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ESLA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ESLA (6) vs VIVS (0)
Institutional Metric ESLA VIVS Criterion Row Edge
Market Capitalization
Scale
$14.6M $2.4M Larger Scale ESLA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -51.4% Higher Growth ESLA
Operating Margin (TTM)
Profitability
0.0% -10117.0% Higher Margin ESLA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-268.5% -343.1% Higher ROE ESLA
52-Week Range Position
Momentum
5% ($0–$2) 5% ($0–$3) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.56β · 339% Vol 0.83β · 480% Vol Lower Realized Risk ESLA
Unified Institutional Score
Composite Signal
46.0 / 100 (HOLD) 39.0 / 100 (SELL) Higher Composite ESLA
Trailing 12M Revenue (USD)
Operating Scale
N/A $112,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 9.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.4M (-268.5% ROE) -$11M EBITDA ($1.4M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VIVS +102.8 pp
ESLA: -38.11% · VIVS: +64.69%
3M Horizon VIVS +55.63 pp
ESLA: -53.71% · VIVS: +1.92%
6M Horizon ESLA +8.37 pp
ESLA: -69.88% · VIVS: -78.25%
1Y Horizon ESLA +5.69 pp
ESLA: -81.3% · VIVS: -86.99%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ESLA vs VIVS. Trailing 12-month operating profitability (ESLA 0.0% vs VIVS -10117.0%) and valuation multiples (ESLA N/M vs VIVS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ESLA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-268.5% · N/M
VIVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$112,000
Gross MarginN/A
Op. Margin-10117.0%
ROE / Fwd P/E-343.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ESLA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ESLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VIVS BREAKDOWN
73d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact VIVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ESLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $14.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VIVS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and -10117.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ESLA vs VIVS Key Questions & Quantitative Answers

As of Nov 19, 2026, Estrella Immunopharma, Inc. (ESLA) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ESLA carries a Unified Composite Score of 46.0/100 (HOLD) at $0.34 (N/M Forward P/E, 0.0% operating margin), whereas VIVS carries 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin). Technical & Structure Timing Caution: ESLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.5); meanwhile VIVS is in a Breakdown options structure phase (RSI 75.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ESLA leads the Growth & Scale pillar: ESLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VIVS at -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin). On trailing 12-month operating scale, ESLA generates N/A in USD-normalized revenue versus $112,000 for VIVS. In operating R&D and SG&A reinvestment, ESLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VIVS.

VIVS screens cheaper on headline valuation multiples. ESLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ESLA (-268.5% ROE) versus VIVS (-343.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ESLA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.56β · 339% Vol realized risk). By comparison, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.